These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 20153543)

  • 1. The clinical and economic burden of non-adherence with oral bisphosphonates in osteoporotic patients.
    Hiligsmann M; Rabenda V; Bruyère O; Reginster JY
    Health Policy; 2010 Jul; 96(2):170-7. PubMed ID: 20153543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential clinical and economic impact of nonadherence with osteoporosis medications.
    Hiligsmann M; Rabenda V; Gathon HJ; Ethgen O; Reginster JY
    Calcif Tissue Int; 2010 Mar; 86(3):202-10. PubMed ID: 20205345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cost effectiveness of zoledronic acid 5 mg for the management of postmenopausal osteoporosis in women with prior fractures: evidence from Finland, Norway and the Netherlands.
    Akehurst R; Brereton N; Ariely R; Lusa T; Groot M; Foss P; Boonen S
    J Med Econ; 2011; 14(1):53-64. PubMed ID: 21222506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A review of the cost effectiveness of bisphosphonates in the treatment of post-menopausal osteoporosis in Switzerland.
    Lippuner K; Pollock RF; Smith-Palmer J; Meury T; Valentine WJ
    Appl Health Econ Health Policy; 2011 Nov; 9(6):403-17. PubMed ID: 21910511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost effectiveness of fracture prevention in postmenopausal women who receive aromatase inhibitors for early breast cancer.
    Ito K; Blinder VS; Elkin EB
    J Clin Oncol; 2012 May; 30(13):1468-75. PubMed ID: 22370313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost effectiveness of teriparatide and PTH(1-84) in the treatment of postmenopausal osteoporosis.
    Borgström F; Ström O; Marin F; Kutahov A; Ljunggren O
    J Med Econ; 2010; 13(3):381-92. PubMed ID: 20604678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The necessity of cost-effectiveness analysis in osteoporosis].
    Lamy O; Krieg MA
    Rev Med Suisse; 2007 Jun; 3(115):1521-5. PubMed ID: 17682796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The clinical and economic burden of poor adherence and persistence with osteoporosis medications in Ireland.
    Hiligsmann M; McGowan B; Bennett K; Barry M; Reginster JY
    Value Health; 2012; 15(5):604-12. PubMed ID: 22867768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of bisphosphonate therapies for women with postmenopausal osteoporosis: implications of improved persistence with less frequently administered oral bisphosphonates.
    Earnshaw SR; Graham CN; Ettinger B; Amonkar MM; Lynch NO; Middelhoven H
    Curr Med Res Opin; 2007 Oct; 23(10):2517-29. PubMed ID: 17825128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of adherence on lifetime fractures in osteoporotic women treated with daily and weekly bisphosphonates.
    Danese MD; Badamgarav E; Bauer DC
    J Bone Miner Res; 2009 Nov; 24(11):1819-26. PubMed ID: 19419313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost of non-persistence with oral bisphosphonates in post-menopausal osteoporosis treatment in France.
    Cotté FE; De Pouvourville G
    BMC Health Serv Res; 2011 Jun; 11():151. PubMed ID: 21702989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of enhancing adherence with oral bisphosphonates treatment in osteoporotic women: an empirical approach based on healthcare utilisation databases.
    Scotti L; Arfè A; Zambon A; Merlino L; Corrao G
    BMJ Open; 2014 Mar; 4(3):e003758. PubMed ID: 24662445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost effectiveness of denosumab compared with oral bisphosphonates in the treatment of post-menopausal osteoporotic women in Belgium.
    Hiligsmann M; Reginster JY
    Pharmacoeconomics; 2011 Oct; 29(10):895-911. PubMed ID: 21692551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Annual zoledronic acid for osteoporosis.
    BMJ Group
    Drug Ther Bull; 2008 Dec; 46(12):93-6. PubMed ID: 19056701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of strontium ranelate versus risedronate in the treatment of postmenopausal osteoporotic women aged over 75 years.
    Hiligsmann M; Bruyère O; Reginster JY
    Bone; 2010 Feb; 46(2):440-6. PubMed ID: 19716940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost effectiveness of secondary vs tertiary prevention for post-menopausal osteoporosis.
    Mueller D; Gandjour A
    Appl Health Econ Health Policy; 2011 Jul; 9(4):259-73. PubMed ID: 21682353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Markov model simulation of the impact of treatment persistence in postmenopausal osteoporosis.
    Cotté FE; Fautrel B; De Pouvourville G
    Med Decis Making; 2009; 29(1):125-39. PubMed ID: 18566486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of strontium ranelate for the prevention and treatment of osteoporosis.
    Hiligsmann M; Vanoverberghe M; Neuprez A; Bruyère O; Reginster JY
    Expert Rev Pharmacoecon Outcomes Res; 2010 Aug; 10(4):359-66. PubMed ID: 20715911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of gastro-resistant risedronate tablets for the treatment of postmenopausal women with osteoporosis in France.
    Hiligsmann M; Reginster JY
    Osteoporos Int; 2019 Mar; 30(3):649-658. PubMed ID: 30701342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ["European Guidance 2008" for the diagnosis and management of postmenopausal osteoporosis--what is new and clinically relevant?].
    Bartl R;
    Dtsch Med Wochenschr; 2009 Jan; 134(3):92-4. PubMed ID: 19142840
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.